Table 2 Summary of adverse drug reactions
e | n (%) | |
|---|---|---|
IMP-related adverse events | 95 | 34 (36.6) |
Severity | ||
Mild | 95 | 34 (36.6) |
Moderate | 0 | 0 |
Severe | 0 | 0 |
Change in treatment schedule | ||
None | 93 | 33 (35.5) |
Temporarily interrupted | 2 | 1 (1.1) |
Discontinued | 0 | 0 |
Prior to first intake | 0 | 0 |
Classification according to EAACI guideline | ||
LR | 85 | 32 (34.4) |
SR | 9 | 4 (4.3) |
Grade 0/Nonspecific | 1 | 1 (1.1) |
Dose | ||
300 SQ+ | 16 | 13 (14.0) |
600 SQ+ | 11 | 11 (11.8) |
3,000 SQ+ | 24 | 22 (23.7) |
6,000 SQ+ | 17 | 17 (18.3) |
15,000 SQ+ | 26 | 15 (16.1) |
Dose unknown | 1 | 1 (1.1) |